CA
DAWN

Clearstead Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Clearstead Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-39
Closed -$275 – 2872
2025
Q3 		$275 Buy
39
+36
+1,200% +$248 ﹤0.01% 2820
2025
Q2 		$20 Buy
+3
New +$21 ﹤0.01% 2708
2025
Q1 		– Sell
-5
Closed -$64 – 2227
2024
Q4 		$64 Buy
+5
New +$70 ﹤0.01% 2058

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clearstead Advisors's DAWN Position: Q4 2025 in Review

Clearstead Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q4 2025, closing a stake of 39 shares — an estimated $275 sold.

Clearstead Advisors first reported a position in DAWN in Q4 2024 and held it in 3 quarters. The position peaked at $275 in Q3 2025. 183 funds tracked by Wall St. Rank hold DAWN as of Q4 2025.

  • Clearstead Advisors reported no remaining Day One Biopharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Clearstead Advisors sold 39 Day One Biopharmaceuticals shares in Q4 2025, an estimated $275.
  • Clearstead Advisors first reported a position in Day One Biopharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Clearstead Advisors's Day One Biopharmaceuticals position peaked at $275 in Q3 2025.
  • 183 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.